CAR-T Cell Therapy Computing
Dual-channel target discovery + de novo Binder design + pMHC 3D structure validation
5-step dry-computing pipeline--from HLA typing + variant detection to CAR Binder de novo design + structure validation. Breaks through traditional scFv limitations, using AI to design protein Binders from scratch, validated by 2024 Nature BME.
Pipeline Flow
End-to-end dry-computing loop
Core Tools
Core Advantages
Dual-channel Target Discovery
VCF neoantigen screening + RNA-seq differential expression dual-channel cross-validation, breaking through single-channel limitations
de novo Binder Design
RFdiffusion + ProteinMPNN de novo protein Binder design, breaking through scFv affinity and stability bottlenecks
pMHC 3D Structure Validation
Protenix atomic-level structure validation (pLDDT=95.4, ipTM=0.977), reducing false positives
Capability Coverage
85%USER SCENE
How This Technology Serves Patients
B2B2C: Through hospitals/doctors, this pipeline reaches these end-user scenarios
Start Your Project CAR-T Cell Therapy Computing
Start with just 1 project, no team needed.